A Phase III Randomized Placebo-Controlled Study Evaluating Regorafenib Following Completion of Standard Chemotherapy for Patients With Stage III Colon Cancer

Trial Profile

A Phase III Randomized Placebo-Controlled Study Evaluating Regorafenib Following Completion of Standard Chemotherapy for Patients With Stage III Colon Cancer

Recruiting
Phase of Trial: Phase III

Latest Information Update: 23 Sep 2017

At a glance

  • Drugs Regorafenib (Primary)
  • Indications Colon cancer
  • Focus Therapeutic Use
  • Acronyms ARGO
  • Most Recent Events

    • 03 Jun 2016 Planned End Date changed from 1 Oct 2024 to 1 Jan 2025.
    • 03 Jun 2016 Planned primary completion date changed from 1 Aug 2023 to 1 Nov 2023.
    • 03 Jun 2016 Status changed from not yet recruiting to recruiting.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top